Skip to Content

Join the 'Omontys' group to help and get support from people like you.

Omontys News

Nearly a Third of Drugs Hit by Safety Issues After FDA Approval

Posted 10 May 2017 by Drugs.com

WEDNESDAY, May 10, 2017 – Safety problems emerge with nearly one in three prescription drugs after they've been approved by the U.S. Food and Drug Administration, a new study reveals. Researchers examined data on drugs approved by the FDA between 2001 and 2010, with follow-up through 2017. The investigators found that 32 percent of the drugs had safety issues after approval. "That is very rarely ...

Anemia Drugs May Not Boost Kidney Patients' Well-Being: Study

Posted 16 Feb 2016 by Drugs.com

MONDAY, Feb. 15, 2016 – The pricey anemia drugs often given to people with chronic kidney disease may make no difference in how they feel day to day, a new research review confirms. Researchers said the study results back up current guidelines on how to use the drugs, called erythropoietin-stimulating agents (ESAs). These include the injection drugs marketed under the names Procrit, Epogen and ...

FDA Medwatch Alert: Omontys (peginesatide) Injection by Affymax and Takeda: Recall of All Lots - Serious Hypersensitivity Reactions

Posted 25 Feb 2013 by Drugs.com

ISSUE: Affymax, Inc. and Takeda Pharmaceutical Company Limited along with the U.S. Food and Drug Administration (FDA) are informing the public of a voluntary recall of all lots of OMONTYS® (peginesatide) Injection to the user level as a result of new postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which can be life-threatening or fatal. To date, fatal ...

Ask a Question

Further Information

Related Condition Support Groups

Anemia Associated with Chronic Renal Failure

Omontys Patient Information at Drugs.com